With an alarming rate of antimicrobial resistance, it becomes essential for the treating dermatologist to familiarize himself with the newer available antimicrobial agents. It has been seen that these drugs allow successful therapeutic outcomes in those patients where conventional antimicrobial therapy is ineffective. This review will throw light on the following newer antimicrobial drugs, namely linezolid, daptomycin, quinupristin/dalfopristin, tigecycline, oritavancin and dalbavancin.
No takes yet. Share an insight, caveat, or question.
Aditya K Bubna (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: